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1  | INTRODUC TION
Copy number variants (CNVs) are DNA segments larger than 1 kilobase 
and present at variable copy number compared to a reference genome. The 
involvement of CNVs on Autism spectrum disorder (ASD) susceptibility is 
well‐established.1‐3 In fact, ASD individuals show an increased burden of 
genic CNVs compared to control subjects.4 CNVs can affect gene expres‐
sion, therefore, contributing to disease pathogenesis, by several mecha‐
nisms, including gene dosage, gene interruption, position effects, gene 
fusion and unmasking of recessive alleles or polymorphisms.5
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Abstract
Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders char‐
acterized by high heritability. It is known that genetic factors contribute to ASD 
pathogenesis. In particular, copy number variants (CNVs) are involved in ASD suscep‐
tibility and can affect gene expression regulation. 2p11.2 microdeletions encompass‐
ing ELMOD3, CAPG and SH2D6 genes have been described in four unrelated ASD 
families. The present study revealed that this microdeletion is responsible for the 
production of a chimeric transcript generated from the fusion between ELMOD3 and 
SH2D6. The identified transcript showed significantly higher expression levels in sub‐
jects carrying the deletion compared to control subjects, suggesting that it is not 
subjected to nonsense‐mediated decay and might encode for a chimeric protein. In 
conclusion, this study suggests the possible involvement of this gene fusion, together 
with the other previously identified variants, in ASD.
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Gene fusions are well studied in cancer genetics, as chimeric 
genes have an important role in different cancers. They can occur 
when CNV breakpoints disrupt two genes encoded on the same 
chromosomal strand.
Some studies have previously investigated whether CNVs gen‐
erating fusion transcripts may have an impact on ASD susceptibil‐
ity6 obtaining negative results. However, fusion transcripts were 
not detected for 80% of CNVs tested and the only CNV resulting 
in a fusion transcript was present in ASD and control subjects 
at similar rate.6 In another study, Pagnamenta et al detected a 
DOCK4‐IMMP2L fusion transcript in both ASD subjects and their 
non‐affected family members. This fusion transcript was expressed 
at very low levels compared to the wild‐type transcript. In fact, 
IMMP2L portion of the fusion gene was out of frame leading to a 
premature stop codon and likely to nonsense‐mediated decay of 
the fusion transcript.7
Another indirect way, by which CNVs can alter gene expres‐
sion, is the disruption of a gene regulatory landscape. Gene tran‐
scription is regulated by cis‐acting elements that can be separated 
from their target gene by the coding sequences of neighbouring 
genes.8
We conducted a comprehensive genetic analysis of a Sardinian 
family (AUT003) consisting of two siblings affected by ASD and 
their unaffected parents.9 Genetic studies conducted on Sardinian 
population have been proven fundamental for the identification of 
genetic loci linked to several complex diseases.10‐13 We identified a 
rare heterozygous 2p11.2 deletion, including the last coding exons 
of ELMOD3, the entire CAPG gene and the first non‐coding exon of 
SH2D6, in both ASD siblings inherited from their unaffected mother 
(Figure 1A). Interestingly, two similar heterozygous 14 and one ho‐
mozygous 15 deletions have been reported in three independent 
ASD families, supporting the clinical relevance of this locus for ASD 
(Figure 1A).
ELMOD3 and SH2D6 genes are transcribed in the same di‐
rection, thus the deletion might have generated a gene fusion 
as hypothesized by Lahbib et al.15 Since copy number loss up‐
stream a gene can affect its expression, this work aims to explore 
the impact of this gene deletion on SH2D6 gene expression and 
the possible formation and expression of a fusion transcript be‐
tween ELMOD3 and SH2D6 genes in deletion carriers compared to 
healthy individuals.
2  | MATERIAL S AND METHODS
Given space constraints in the main text, detailed Material and 
Methods can be found in the Supplementary Material and Methods 
file.
3  | RESULTS
We evaluated SH2D6 gene expression in AUT003 family and 17 
healthy individuals using two different assays as described in 
Materials and Methods. The first assay did not reveal any detect‐
able SH2D6 product in all the tested samples. Since the forward 
primer maps on the deleted region, the absence of SH2D6 expres‐
sion in the individuals with the deletion implies that the wild‐type 
SH2D6 locus is not transcribed. In fact, SH2D6 is expressed at very 
low levels in whole blood (GTEx data, Figure 2A). The second assay 
revealed that, as expected, SH2D6 was undetectable in all subjects 
without the deletion, including the unaffected father (AUT003.1) 
(Figure 1B). Interestingly, a significant increase of SH2D6 mRNA ex‐
pression levels was detected in the two ASD probands (about 320 
folds [P < .0001] and 190 folds [P < .0001] relative to controls, in 
AUT003.3 and AUT003.4, respectively), as well as in their unaf‐
fected mother (AUT003.2, about 245 folds [P < .0001]; Figure 1B).
To understand the reasons why SH2D6 becomes highly ex‐
pressed in PBMCs of subjects carrying the deletion, we explored 
two possible mechanisms: (a) loss of a silencer or an insulator in the 
deleted region upstream SH2D6, or acquisition of an enhancer; (b) 
gene fusion between SH2D6 and ELMOD3.
The loss of the upstream region of SH2D6 could have disrupted 
its regulatory landscape affecting its expression. In fact, it is possi‐
ble that the deletion of a silencer of an insulator, or approaching an 
enhancer, results in gene up‐regulation. Since we evaluated SH2D6 
gene expression levels in PBMCs, we investigated SH2D6 regulatory 
region in GM12878 cell line finding a large number of regulatory ele‐
ments upstream SH2D6 (Figure 2B). Interestingly, most SH2D6 gene 
region is heterochromatic and methylated, confirming that this gene 
is not transcribed in GM12878 cell line. GeneHancer did not reveal 
elements interacting with SH2D6 in the deleted region (Figure 2B).
We evaluated the possible presence of a transcript fusion be‐
tween ELMOD3 and SH2D6 by PCR.
F I G U R E  1   2p11.2 microdeletion and ELMOD3‐SH2D6 gene fusion detection. A, Schematic representation of the microdeletion identified 
in AUT003 family in the present study and in other three ASD families. Red arrows indicate the primers used in the first gene expression 
assay (SH2D6 exon 1 [forward] and SH2D6 exons 2‐3 [reverse]). Purple arrows indicate the primers used in the second gene expression 
assay (SH2D6 exons 11‐12 [forward] and exons 13‐14 [reverse]). Green arrows indicate the primers used for the fusion transcript (ELMOD3 
exon 10 and SH2D6 exon 2‐3); B, SH2D6 gene expression assay in AUT003 family members and in controls. Bar plots represent fold change 
with upper/lower limits relative to controls; C, ELMOD3‐SH2D6 fusion transcript and SH2D6 gene expression detection in AUT003 family 
members and in controls. Bar plots represent delta Ct; D, Example of ELMOD3‐SH2D6 transcript fusion and SH2D6 (primers used in the 
second assay) qRT‐PCR curves obtained from one sample carrying the deletion. Curves on the left part of the figure refer to the reference 
gene (TFRC) and curves on the right part refer to the transcripts of interest; E, Sequence electropherogram showing the point of fusion 
between ELMOD3 exon 11 and SH2D6 exon 2; F, Schematic representation of the fusion transcript
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F I G U R E  2   SH2D6 normal tissues gene expression and regulation analysis. A, SH2D6 gene expression levels across different tissues (GTEx 
Data Portal). B, SH2D6 regulatory region analysis using chromatin state segmentation analysis data from ENCODE/Broad, CpG methylation 
data from ENCODE/HAIB and GeneHancer data
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A PCR product of the expected size was obtained for ASD pro‐
bands and their unaffected mother while, as expected, no amplifica‐
tion was detected in controls.
The expression levels of this fusion transcript (evaluated using prim‐
ers mapping in ELMOD3 exon 10 and SH2D6 exon 2‐3) were compared 
to that of SH2D6 (SH2D6 exon 13 and exon 14 primers, PCR product: 
99bp) in deletion carriers by qRT‐PCR. Delta Cts (Figure 1C) revealed 
that transcript expression levels detected using both assays do not dif‐
fer implying that the increased expression of SH2D6 in subjects with 
the deletion is only due to this fusion transcript (Figure 1C and 1).
Sequencing analysis confirmed the presence of this fusion tran‐
script in both ASD siblings and their unaffected mother (Figure 1E 
and 1). ExPASy Translate tool predicted that the cDNA sequence re‐
sulted by the fusion of ELMOD3 and SH2D6 transcript would encode 
for a protein of 258 amino acids (aa), including the first 246 aa of 
ELMOD3 and 12 new amino acids encoded by the non‐coding por‐
tion of SH2D6 before a stop codon. Therefore, this chimeric protein 
would not include the canonical SH2D6 coding sequence and an in‐
terrupted domain of ELMOD3 (ELMO domain: 170‐324 aa), thus pos‐
sibly impacting its function. As expected, Western blot for SH2D6 
did not reveal any protein product since the antibody recognizes an 
epitope which is not present in the predicted chimeric protein se‐
quence (data not shown).
4  | DISCUSSION
The complex ASD phenotype implied that multiple gene variants 
participate to ASD phenotypic manifestations. Previous studies 
have investigated the presence of fusion transcripts in ASD.6,7 
However, the detected fusion transcripts were present at similar 
levels in both ASD patients and healthy individual or were ex‐
pressed at much lower levels compared to wild‐type transcript 
suggesting that they are subjected to nonsense‐mediated decay. 
To our knowledge, our study is the first that highlights the possible 
contribute of a chimeric gene in ASD phenotype. In fact, the so ev‐
ident and detectable expression of the transcript produced by the 
identified fusion gene in the cells of deletion carriers suggests that 
this transcript does not undergo mechanisms of nonsense‐medi‐
ated decay. Further investigations will be necessary to reveal the 
possible translation of a chimeric protein and its possible function, 
perhaps contributing together with other variants (as already sug‐
gested in our previous work, 9) to generate the ASD phenotype.
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